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C-terminal binding proteins (CtBPs) are cotranscriptional
factors that play key roles in cell fate. We have previously shown
that NAD(H) promotes the assembly of similar tetramers from
either human CtBP1 and CtBP2 and that CtBP2 tetramer
destabilizing mutants are defective for oncogenic activity. To
assist structure-based design efforts for compounds that disrupt
CtBP tetramerization, it is essential to understand how NAD(H)
triggers tetramer assembly. Here, we investigate the moieties
within NAD(H) that are responsible for triggering tetramer
formation. Using multiangle light scattering (MALS), we show
that ADP is able to promote tetramer formation of both CtBP1
and CtBP2, whereas AMP promotes tetramer assembly of
CtBP1, but not CtBP2. Other NAD(H) moieties that lack the
adenosine phosphate, including adenosine and those incorpo-
rating nicotinamide, all fail to promote tetramer assembly. Our
crystal structures of CtBP1 with AMP reveal participation of the
adenosine phosphate in the tetrameric interface, pinpointing its
central role in NAD(H)-linked assembly. CtBP1 and CtBP2 have
overlapping but unique roles, suggesting that a detailed un-
derstanding of their unique structural properties might have
utility in the design of paralog-specific inhibitors. We investi-
gated the different responses to AMP through a series of site-
directed mutants at 13 positions. These mutations reveal a
central role for a hinge segment, which we term the 120s hinge
that connects the substrate with coenzyme-binding domains
and influences nucleotide binding and tetramer assembly. Our
results provide insight into suitable pockets to explore in
structure-based drug design to interfere with cotranscriptional
activity of CtBP in cancer.
C-terminal binding proteins (CtBPs) are transcriptional
coregulators that were first identified through interactions with
the C-terminal region of the adenovirus E1A oncoprotein that
modulate E1A transforming activities (1, 2). CtBP1 and CtBP2
regulate cellular processes through binding transcription fac-
tors and recruiting chromatin remodeling enzymes such as
histone deacetylases, methyl transferases, and demethylases to
targeted promoters (3–5). CtBP cotranscriptional function has
been shown to be important in normal embryogenesis in model
organisms (6–9). Knockout experiments in mice reveal distinct
roles for CtBP1 and CtBP2 in development, with the loss of
CtBP2 embryonically lethal, whereas CtBP1-null mice are small
but the majority survive (6).
Numerous lines of evidence implicate human CtBP in cancer
progression. Both CtBP paralogues are global repressors of the
epithelial phenotype and of apoptotic pathways (3) by acting as
corepressors of genes including tumor suppressive proapo-
ptotic factors (Bik, Noxa), cytoskeletal/cell adhesion molecules
(keratin-8, E-cadherin), and cell-cycle inhibitors (4, 10). CtBP
has also been found to be a coactivator of growth and
metastasis-related genes (Tiam1, MDR1, certain Wnt target
genes), which facilitate the epithelial-to-mesenchymal transi-
tion (EMT) (11–14). Consistent with a role in repression of
apoptotic pathways and activation of growth and metastasis,
CtBP is upregulated in a number of cancer tissues including
colorectal cancer (15), melanoma (16), metastatic prostate
cancer (17), esophageal squamous cell carcinoma (18), ovarian
cancer (19), and breast cancer (20, 21). Strikingly, elevated
levels of CtBP in tumor tissue have been correlated with poorer
survival in breast cancer (22), ovarian cancer (19), gastric car-
cinoma (23), and hepatocellular carcinoma (24). Recent results
add to evidence of a link between CtBP and cancer progression
by showing increased survival in mice models for colon cancer
(APCmin/+) (25) and pancreatic adenocarcinoma (CKP) (26)
when CtBP2 levels are lowered by CtBP2+/- heterozygosity.
A unique feature of CtBP is the incorporation of a D-iso-
mer-specific 2-hydroxyacid dehydrogenase (D2-HDH)
domain, which reduces or oxidizes substrates using the co-
enzyme NAD(P)+/NAD(P)H (27, 28). While evidence indicates
that catalytic activity is not required for some CtBP activities
(10, 29), mutant studies suggest that catalytic activity of CtBP
can be important in Drosophila melanogaster development
(30). Regardless of the cellular relevance of this catalytic ac-
tivity, the deep substrate and coenzyme cavities suggest that
CtBP may provide a particularly favorable target for the
development of small-molecule inhibitors in cancer.
Oligomerization of transcriptional factors is an important
mechanism for regulation of gene expression (31, 32). In the
case of CtBP, substantial evidence exists that oligomerization
is linked with NAD(H) binding (5, 29, 33–36), and dimer-
destabilizing mutants inhibit transcriptional function
(37–40). Although assembly of CtBP has primarily beenThis article contains supporting information.
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considered in terms of dimers, there is accumulating evidence
that NAD(H) binding triggers the assembly of two CtBP di-
mers to form tetrameric dimers of dimers (33–35, 41, 42).
Moreover, we have recently shown that tetramer-destabilizing
mutants of CtBP2 are defective for oncogenic activity (42).
Here we explore the moieties within NAD(H) that are
responsible for promoting tetrameric assembly. Our multi-
angle light scattering (MALS) data show that ADP promotes
tetrameric assembly in CtBP1 and CtBP2, whereas AMP pro-
motes tetrameric assembly for only CtBP1. By mutagenesis, we
pinpoint the basis for different AMP responses between the
two paralogs to a short segment that both connects the two
subdomains and participates in the tetrameric interface.
Moieties of NAD(H) lacking the adenosine phosphate are
unable to promote tetrameric assembly. To understand the
structural basis for AMP-linked assembly of CtBP1, we
determined the crystal structure of CtBP1 with AMP, which
reveals a direct interaction involving the adenosine phosphate
in tetramer formation. Thus, this phosphate is critical for the
response of CtBP to binding of NAD(H).
Results
Multiangle light scattering reveals the extent of CtBP1 and
CtBP2 tetrameric assembly in the presence of NAD(H) moieties
To ascertain the basis for NAD(H)-linked tetramer forma-
tion, the level of assembly of CtBP1 and CtBP2 in the presence
of NAD(H) moieties (Fig. S1) was investigated by MALS of
samples eluting from a size-exclusion column (SEC). (NAD(H)
refers to either NADH or NAD+.) Previously we demonstrated,
also with SEC-MALS, the linkage between NAD(H) and
tetrameric assembly of CtBP1 and CtBP2 (41).
Results of our SEC-MALS experiments on CtBP1 (28–440)
(herein referred to as CtBP1) and CtBP2 (31–445) (herein
CtBP2) are shown in Figure 1. Consistent with our previous
work (41), CtBP1 is primarily tetrameric in the presence of
10 μM NADH and 10 μM NAD+, with weight average mass
(Mw) of 172 and 169 kDa, respectively. Additionally, 1 mM
ADP and 1 mM AMP also exhibit early elution and high
molecular masses (Mw = 167–173 kDa). CtBP1 in the presence
of the other tested compounds elutes later and shows molec-
ular mass values of 111–128 kDa, similar to CtBP1 in the
absence of any NAD moiety (128 kDa). The observed molec-
ular masses indicate heterogeneous mixtures, primarily of
94 Da dimers and 188 kDa tetramers. Given that light scat-
tering provides weight average molecular mass estimates (Mw)
(43), one can calculate approximate molar fractions of dimers
and tetramers, assuming that those are the only species
contributing to the light scattering (see Experimental
procedures). Based on these assumptions, CtBP1 in NADH,
NAD+, AMP, and ADP is approximately 64–73% tetrameric,
whereas in the other tested compounds, CtBP1 is 10–23%
tetrameric for the data shown in Figure 1 (Table S1).
The elution volumes and MALS molecular mass values for
CtBP2 show a similar pattern to those for CtBP1, with the
notable exception of the response to AMP. In the presence of
10 μM NADH, 10 μM NAD+, and 1 mM ADP, the MALS
measured molecular masses for CtBP2 are 169–176 kDa.
CtBP2 in the presence of 1 mM AMP exhibits a MALS mo-
lecular mass of 132 kDa, only slightly higher than in the
absence of any NAD moiety and much lower than with 1 mM
ADP. For the the other tested compounds, the molecular
masses range from 121 to 129 kDa, similar to 129 kDa for
CtBP2 in the absence of any NAD moiety. Estimating the
fractions of dimer and tetramer as described above, CtBP2 in
NADH, NAD+, and ADP under these conditions is 63–73%
tetramer. For the other tested compounds, CtBP2 is estimated
to be 15–24% tetramer (Table S1).
Concentration dependence of the ADP and AMP-linked
assembly of CtBP1 and CtBP2
Previously we demonstrated that NADH and NAD+ pro-
mote tetrameric assembly of CtBP1 and CtBP2 with apparent
EC50 values in the range of 50–150 nM (41). As discussed
above, ADP promotes the tetrameric assembly of CtBP1 and
CtBP2, whereas AMP promotes the tetrameric assembly of
CtBP1. Figure 2 shows the measured MALS Mw values for
CtBP1 and CtBP2 as a function of ADP and AMP concen-
tration. (Individual results along with additional replicates are
provided in Table S2.) Fitting the molecular mass dependence
on ADP concentration (see Experimental procedures) in-
dicates Mw values of 120 kDa and 126 kDa for CtBP1 and
CtBP2, respectively, at low ADP concentrations rising to
170 kDa and 171 kDa at high ADP concentration for the
measured conditions. The fitting yields an EC50 value for the
effect of ADP promoting tetramer formation of about 52 μM
for CtBP1 and 43 μM for CtBP2. Fitting the data for AMP
yields an EC50 value of about 66 μM for CtBP1. Thus, although
ADP and AMP (for CtBP1) promote tetramer formation as
does NAD(H), the concentrations of AMP and ADP required
for tetrameric assembly are approximately three orders of
magnitude higher than required for NAD(H).
Competition between NAD(H) and nontetramer inducing NAD
moieties
The inability of those NAD moieties that lack adenosine
phosphate to promote CtBP tetramer formation could result
from a lack of binding or binding that does not induce
structural changes that stabilize tetramers. To test for specific
binding, we investigated the ability of these compounds to
interfere with NADH-linked tetramerization. Figure 3 shows
SEC/MALS results for CtBP1 and CtBP2 in the presence of
50 nM NADH (slightly below the EC50 for tetramer formation
(41)). Under these conditions, the MALS determined molec-
ular masses of 128 kDa and 134 kDa for CtBP1 and CtBP2,
suggesting approximately 22% and 25% tetramer, respectively.
Addition of 2 mM adenosine reduces the molecular masses by
9 kDa, lowering the estimated tetramer fractions to 15% and
18%, respectively. Thus, adenosine is able to interfere with
NADH-linked tetramer assembly, presumably by direct bind-
ing, which highlights the importance of the adenosine phos-
phate to promote tetramer formation. (The effect of adenosine
showing lower MALS Mw values is also evident in Figure 1,
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suggesting a very small amount of residual bound NAD(H)
may be present in those experiments, see below.) This series of
experiments provides evidence that nicotinamide ribose and
nicotinamide may also interfere with tetramer formation, but
only to a very small extent. Although slight, the differences do
appear to be reproducible (Table S3). These results suggest
that adenosine, along with possibly nicotinamide and nico-
tinamide ribose, inhibits NADH-linked tetrameric assembly of
CtBP by binding in the NADH pocket, albeit at much lower
affinity. Thus, binding into the adenosine or nicotinamide
ribose pockets is not sufficient to cause tetrameric assembly
unless the adenosine phosphate is present.
Structural investigation of AMP binding to CtBP1
Our earlier crystal structures of CtBP1 and CtBP2 showed
that the adenosine phosphate of NAD(H) interacts with a
conserved Arg (184 in CtBP1, 190 in CtBP2), which then
participates in a hydrogen bond with the main chain carbonyl
oxygen of Asp 2090/2150 (CtBP1/CtBP2, primes designate a
residue in a partner subunit) across the tetrameric interface
(41, 44). (The similarity of this interaction in CtBP1 and CtBP2
is shown in Fig. S2.) To ascertain if AMP promotes tetramer
assembly of CtBP1 in a similar fashion, we determined the
crystal structure of CtBP1 (28–375) in complex with AMP at
2.45 Å resolution (Fig. 4A). (Crystallization of CtBP1 required
1mM ADP          (167 kDa)
1mM AMP   - - - (173 kDa)
10 M NADH         (172 kDa)
10 M NAD+   - - - (169 kDa)
No NAD moiety (128 kDa)
2mM Nicotinamide (128 kDa)
2mM Nicotinamide ribose (123 kDa)
0.5mM NicoMonoNucleotide (122 kDa)
2mM Adenosine (111 kDa)
CtBP1 (28-440)
1mM AMP - - - (132 kDa)
No NAD moiety (129 kDa)
2mM Nicotinamide (129 kDa)
2mM Nicotinamide ribose (129 kDa)
0.5mM NicoMonoNucleotide (129 kDa)
2mM Adenosine (121 kDa)
10 M NADH          (176 kDa)
10 M NAD+   - - - (169 kDa)















































Figure 1. SEC trace and MALS molecular masses for A, CtBP1 (28–440) and B, CtBP2 (31–445) in the presence of NAD(H) moieties. The lines
(continuous or dashed) show the light-scattering Rayleigh ratio (arbitrary units) for protein elution from the SEC column, and the small squares show the
MALS molecular mass measurements across the elution peaks. The plots reveal that tetramer formation is promoted by NADH, NAD+, and ADP in both
CtBP1 and CtBP2, but by AMP only in CtBP1 at the concentrations shown. (The elution peak concentrations ranged from 1.6 μM to 3.1 μM for CtBP1 and
1.6 μM to 2.0 μM for CtBP2. Tabulation of these data, along with replicate experiments, is provided in Table S1.)
Assembly of tetrameric CtBP
J. Biol. Chem. (2021) 296 100351 3
the removal of the last 65 residues (41); CtBP1 (28–375) shows
similar AMP-dependent tetramerization as does CtBP1
(28–440), Table S2.) As discussed in Experimental procedures,
careful purification of CtBP1 (28–375) in the presence of
5 mM AMP was required to completely remove bound
NAD(H) that is apparently acquired during expression in
E. coli. Eventual success became clear from crystallographic
analysis showing the electron density for AMP (Fig. 4B) but no
observable density for the remainder of the NAD(H) cofactor.
The cocrystal structure of AMP bound to CtBP1 (28–375)
confirms that AMP binds nearly identically to the AMP
portion of NADH. In particular, the adenosine phosphate
maintains charge-stabilized hydrogen bonding with Arg 184,
which then forms a hydrogen bond across the tetrameric
interface with the main-chain carbonyl oxygen of Asp 209
(Fig. 4B), which is nearly identical to that observed in CtBP1
and CtBP2 bound to NAD(H) (Fig. S2). Our finding that AMP
triggers tetramer formation, but adenosine interferes with
NADH-linked tetrameric assembly (Fig. 3), demonstrates that
this phosphate is critical for tetramer formation, apparently by
localizing Arg 184 for favorable hydrogen bonding across the
interface.
Distinct responses of CtBP1 and CtBP2 to AMP
To determine the basis for the distinct response of CtBP1
and CtBP2, we created a series of mutants at positions that
have different residues in CtBP1 and CtBP2. Given the struc-
tural and sequence similarity between CtBP1 and CtBP2
(particularly in the dehydrogenase domain, with 88.7% amino
acid sequence identity, Fig. S3), it was perhaps surprising to
find such a striking difference in the response of these two
proteins to AMP. (The minimal dehydrogenase domains of
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Figure 3. Competition between 50 nM NADH and NAD moieties. A,
CtBP1 and (B) CtBP2 SEC-MALS experiments with the column equilibrated
with 50 nM NADH (blue), followed by 50 nM NADH plus 2 mM nicotinamide
(purple), 2 mM nicotinamide ribose (green), or 2 mM adenosine (red).
Adenosine showed the largest shift, lowering the observed molecular mass
by 9 kDa under these conditions for both CtBP1 and CtBP2, with nicotin-
amide ribose and nicotinamide showing smaller, but consistent, shifts. For
the experiments shown, the elution peak protein concentrations ranged
from 1.6 to 1.7 μM, for CtBP1 and 0.59 to 0.63 μM, for CtBP2. (The column
elution volumes for CtBP2 are generally larger than those of CtBP2, as
evidenced in the difference between A and B. Individual data and replicates
tabulated in Table S3.)
Figure 2. Dependence of MALS-determined CtBP molecular masses as a
function of ADP and AMP concentrations. The data were fitted with Prism
version 8 (see Experimental procedures). A, ADP dependent MALS-
measured Mw values for CtBP1 (28–440) and CtBP2 (31–445). The data
shown are for measurements of CtBP1 in triplicate and CtBP2 in duplicate.
The fitted curve for CtBP1 indicates molecular masses of 118 kDa at low ADP
and 170 kDa at high ADP, suggesting tetrameric fractions of 14% and 66%,
respectively. The fitted curve for CtBP2 indicates molecular masses of
126 kDa at low ADP and 171 kDa at high ADP, suggesting tetrameric
fractions of 19% and 66%, respectively. B, AMP-dependent MALS-measured
Mw values for CtBP1 (28–440) and CtBP2 (31–445). The data shown are for
measurements of CtBP1 in duplicate, but single measurements for CtBP2.
The fitted curve for CtBP1 indicates molecular masses of 126 kDa at low
AMP and 177 kDa at high AMP (with slightly higher protein concentrations
than the ADP experiments) suggesting tetrameric fractions of 21% and 79%,
respectively. (Individual data and additional replicates tabulated in
Table S2.)
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responses as the equivalent paralog with the full C terminus
(Table S4) strongly suggesting that the basis for distinct re-
sponses resides within the minimal dehydrogenase domains.)
We first explored those residues with sequence differences in
contact with NADH. Five residues with different amino acid
identity between CtBP1 and CtBP2 have atoms within 5 Å of
NADH (Figs. S3 and S4). For each of the five, we mutated the
CtBP1 residue to that in CtBP2 to determine the contribution
of each to the distinct AMP responses. One particularly
interesting mutant, V185T, enhanced tetramerization in the
presence of AMP (Fig. 5A). The basis for the enhanced as-
sembly of CtBP1 V185T became clear from the crystal struc-
ture, which revealed a well-ordered water molecule bridging
the Thr hydroxyl and a phosphate on AMP in CtBP-V185T
(Fig. 4C). This ordered water molecule stabilizes a cluster of
water molecules in the vicinity of bound AMP, which
apparently stabilizes bound AMP over that in wild-type CtBP1.
The other single site mutants were similar to wild-type in their
response to AMP, except for L182F, which is discussed in
Figure S5. Combinations of these mutants did not convert
CtBP1 into a form that displayed the observed CtBP2 response
to AMP (Table S4). Thus, other residues must be responsible
for the distinct AMP response of the two paralogs.
As a result, we widened the search of different residues
between CtBP1 and CtBP2 to those in close structural prox-
imity to the mutated coenzyme contacting residues and/or the
tetrameric interface. Addition of six more residues created an
11-mutant form, termed “11Mut” (Fig. S3). 11Mut, along with
various combinations of a smaller number of mutations, also
did not convert CtBP1 into the AMP response observed in
CtBP2 (Fig 5C and Table S4). However, adding two additional
changes, V120I and A122S to 11Mut (which included an
S124A mutation in the same peptide segment, Fig. 5D)
reduced the molecular mass to slightly below that of a dimer,
apparently eliminating tetramer formation in the presence of
AMP while maintaining primarily tetrameric form in the
presence of NADH (Fig. 5B). Thus, CtBP1 with these 13
mutations approximates the AMP and NADH behavior of
CtBP2.
This search identified a key peptide segment, including
V120, A122, and the neighboring coenzyme contacting Ser124
as important in the response of AMP binding. This segment,
which we refer to as the “120s hinge,” is one of two segments
that connect the substrate and coenzyme-binding domains
(Fig. 6A). In the 120s hinge, Ser 124 contacts NADH and Ala
122 makes contacts in the tetrameric interface (Fig. 6), and
thus this hinge region is in a critical position to both sense
binding in the coenzyme pocket and contribute to tetrameric
assembly. In the context of wild-type CtBP1, triple mutation of
just the 120s hinge is dimeric (92 kDa) in the presence of
1 mM AMP, but only partially tetrameric (142 kDa) in 10 μM
NADH (Fig. S5). Thus, mutation of the 120s hinge residues is
necessary for weakening the AMP response, but not sufficient
to approximately match the complete CtBP2 response.
The centrality of the 120s hinge was tested by creating the
converse mutants in CtBP2. Mutation of I126V, S128A, and
A130S (Fig. 5D) resulted in protein that maintained a primarily
tetrameric arrangement in the presence of both 1 mM AMP
and 10 μMNADH (Fig. 5C). Thus, mutation of just these three
residues is sufficient to convert CtBP2’s response to AMP and
NADH to be similar to that of CtBP1. These results demon-
strate that the 120s hinge segment is central for the distinct
response of the two CtBP paralogs.
Discussion
NAD(H) is involved in both cotranscriptional activity and
oligomerization of CtBP (5, 29, 33, 36, 37). Although oligo-
merization has most often been considered as dimerization, we
(41) and others (34) have demonstrated that the primary effect
of NAD(H) is to promote assembly of CtBP dimers into tet-
ramers. Moreover, we have recently established the tran-
scriptional relevance of the tetrameric forms by showing that
Figure 4. AMP-bound crystal structures of CtBP1. A, trace of CtBP1
tetramer (WT, residues 28–375) with two subunits shown in cyan and two in
salmon and the four bound AMP moieties shown as van der Waals spheres.
B, omit Fo-Fc electron density map, with AMP and neighboring water mol-
ecules removed, from CtBP1 (WT) AMP structure. Map is contoured at 3σ
(blue) and clearly shows the AMP moiety, whose ionically stabilized
hydrogen bond with arginine 184 positions it to form a hydrogen bond
across the tetrameric interface with the main-chain carbonyl of Asp 209' of a
neighboring subunit. (Apparent hydrogen bonds, with distances of 2.6 Å
and 3.2 Å, are shown as dashed lines.) C, omit Fo-Fc electron density map,
with AMP and neighboring water molecules removed, from the CtBP1
(V185T) AMP structure. Map is contoured at 3σ (blue) and clearly shows the
AMP moiety along with neighboring water molecules that are more well-
ordered than in wild-type. It appears that a well-ordered water molecule
stabilizes the AMP phosphate by forming bridging hydrogen bonds linking
a phosphate oxygen with the mutant threonine hydroxyl (dashed lines, 2.6 Å
and 2.7 Å), providing additional stabilization for Arg 184 and the tetrameric
interface.
Assembly of tetrameric CtBP
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tetramer-destabilizing mutants of CtBP2 are defective for
oncogenic activity (42). Our results here have identified the
phosphate groups as central for NAD(H)-linked assembly of
tetrameric CtBP and also identified an important difference
between CtBP1 and CtBP2 that emanates from a short peptide
segment that connects the two subdomains. These findings are
key for defining how CtBP exerts its cotranscriptional effects
and for efforts to design inhibitors that could become lead
compounds for antineoplastic agents.
The results presented here provide new insight into the
trigger for CtBP oligomerization. Madison et al. (34) proposed
that the binding of NAD(H) triggered the formation of a
dimer as a result of a hydrogen bond between Trp 318 and the
nicotinamide. Dimeric assembly is a prerequisite for assembly
of two dimers into a tetramer (34, 41). The conformation of
Trp 318 is essentially identical in CtBP1 bound to NAD+ and
AMP lacking the nicotinamide moiety (Fig. S7), arguing
against the hypothesis that a direct interaction between the
nicotinamide and Trp 318 is key for NAD(H) triggered as-
sembly of CtBP. Moreover, our finding that AMP or ADP can
trigger assembly strongly suggests that interactions with the
nicotinamide ring are dispensable for dimer and tetramer
formation, as nicotinamide, nicotinamide ribose, and nico-
tinamide nucleotide all fail to trigger CtBP oligomerization.
Our light scattering experiments, both presented here and
earlier (41), strongly suggest that CtBP1 and CtBP2 assemble
into dimers even in the absence of NAD(H), which is not
surprising given the very extensive dimeric interface
(2500 A2). Rather, our evidence indicates that it is the
interaction of the adenosine phosphate with Arg 184/190 that





13 Mut 1mM AMP (87kDa)
13 Mut 10uM NADH (169 kDa)
11 Mut 10uM NADH (173 kDa)
“120s 3Mut” 10uM NADH (178 kDa)
“120s 3Mut” 1mM AMP (175 kDa)
V185T 1mM AMP ( 183 kDa)
V185T 100uM AMP (172 kDa)wild-type 1mM AMP (173 kDa)


















































Select CtBP1 and CtBP2 Mutants
Full alignment with mutants in Fig. S3
Figure 5. SEC trace and MALS molecular masses showing the response of CtBP1 and CtBP2 mutants to AMP and NADH. The lines show the light-
scattering Rayleigh ratio (arbitrary units) for protein elution from the SEC column, and the small squares show the MALS molecular mass measurements
across the elution peaks. A, traces comparing the mutant V185T with wild-type CtBP1 in 1 mM and 100 μM AMP. Note the substantially greater molecular
masses for the V185T traces, indicating greater stabilization of the tetrameric form with bound AMP compared with wild-type. B, traces showing the CtBP1
11 mutant (L124A, L182F, V185T, V211I, A214S, L217V, G238N, T264A, E330A, K333T, K348R), which responds to 1 mM AMP and 10uM NADH similarly to
wild-type. In contrast, the 13-mutant form of CtBP1 (adding V120I, A122S to the 11-mutant form) is much more similar to CtBP2 in its response to 1 mM
AMP, exhibiting a primarily dimeric molecular mass (87 kDa) and to 10 μM NADH showing a primarily tetrameric molecular mass. C, traces of CtBP2 mutated
to the CtBP1 residues in the “120s hinge” (I126V, S128A, A130S) respond to both 1 mM AMP and 10 μM NADH very similarly to CtBP1. (Individual data and
replicates tabulated in Table S4. The difference in elution volumes for [A] and the others results from different columns.) D, partial alignment of CtBP1 and
CtBP2 sequences showing key mutations constructed for the data shown in this figure, with NADH contacting residues highlighted in cyan and 120s loop
residues highlighted in yellow. (Full sequence alignment and mutations provided in Fig. S3.)
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Substantial evidence (4, 15–26) suggests that CtBP may be a
useful target for antineoplastic agents. Application of
structure-based drug design approaches requires a detailed
understanding of cotranscriptional activation, which for CtBP
includes defining the trigger for tetramer formation. In
particular, it is important that agents designed to inhibit
NADH binding do not inadvertently promote oligomerization.
Our results demonstrate that binding of ligands in the coen-
zyme pocket does not promote tetramer formation unless the
adenosine phosphate is present. Thus, other portions of the
coenzyme pocket can be exploited in structure-based drug
design to interfere with NAD(H) binding and disrupt CtBP
cotranscriptional activity in cancer.
Our earlier structural analysis of CtBP1 and CtBP2 (44)
revealed a hydrophilic cavity linking the substrate MTOB (4-
methylthio 2-oxobutyric acid) with the pocket binding nico-
tinamide ribose and phosphate (Fig. S8). Targeting this cavity
for inhibitor design should confer specificity, as this cavity is
unique to CtBP1 and CtBP2. Our results here showing that
nicotinamide and nicotinamide ribose do not trigger tetramer
formation suggests a specific strategy for structure-based drug
design. Compounds could be designed that both bind with
high affinity in the substrate pocket (as we have previously
demonstrated (45)) and extend through the hydrophilic cavity
into the nicotinamide pocket to inhibit NADH binding.
Functional differences between CtBP1 and CtBP2 are
evident; for instance, CtBP2 knockouts are embryonically le-
thal in mice, whereas the effect of knocking out CtBP1 is more
subtle (6). Such differences may extend to tumor cells as well,
in which case eventually developing compounds with speci-
ficity for CtBP1 or CtBP2, but not both, may be advantageous.
As a result, it is important to delineate differences even in
proteins as structurally similar as CtBP1 and CtBP2.
The similar NAD(H) concentration dependence for CtBP1
and CtBP2 assembly into tetramers (41) suggests similar co-
enzyme affinity. However, the distinct responses to AMP
identified here highlight an important difference. Our results
demonstrate that a short segment connecting the two CtBP
domains, which we term the 120s hinge, is primarily respon-
sible for distinct paralog responses to AMP binding. The
proximity of the 120s hinge to both the substrate binding
pocket and the tetrameric interface suggests that it could be
possible to target this region to obtain paralog-specific in-
hibitors. Our results also highlighted another important
sequence variation, Thr 191 in CtBP2, which is occupied by
the isosteric, but nonpolar, Val 185 in the homologous posi-
tion in CtBP1. It is likely that the hydrogen bond between Thr
191 and the nicotinamide phosphate of NAD(H) contributes to
the stabilization of coenzyme binding in CtBP2 that is absent
in CtBP1. This interaction is most likely formed in ADP, which
shows similar concentration dependence for both CtBP2 and
CtBP1, but is absent in AMP. Thus, the hydrogen bond be-
tween Thr 191 and the nicotinamide phosphate is likely to be
important for coenzyme binding in CtBP2. Therefore, one
approach to CtBP2-specific inhibitors could include a moiety
that can directly interact with Thr 191 to favor inhibition of
CtBP2 over CtBP1.
In conclusion, our studies demonstrate that the linkage
between NAD(H) binding and CtBP tetramer formation re-
quires the adenosine phosphate of the coenzyme. These results
highlight the nicotinamide ribose pocket as a favorable re-
ceptor for inhibitors whose binding should disrupt tetramer
Figure 6. Structure of CtBP1-AMP highlighting the 120s hinge. A, one subunit showing the two domains spanned by the 120s hinge (green). B, two
subunits contacting at the tetrameric interface. Note the short αE helix in each subunit projecting toward the partner subunits making contacts with the
120s hinge residues. C, tetrameric interactions in the region of the 120s hinge. Note the close proximity of the 120s hinge to the short αE helix of the partner
subunit and to the critical Arg 184, which bridges between the AMP phosphate and partner subunit.
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formation and cotranscriptional activity. An understanding of
the stereochemical details for the assembly of CtBP dimers
into tetramers can, thus, contribute to the development of
highly specific inhibitors of CtBP in cancer.
Experimental procedures
Expression, purification, and mutagenesis of CtBP1 and CtBP2
The expression and purification procedures followed those
of earlier studies (41, 44, 45). CtBP1 and CtBP2 mutants were
created with the QuikChange protocol (Strategene) using the
modified approach of Liu and Naismith (46). The final step in
purification was an FPLC size-exclusion column (Highload 16/
60 Superdex 200 preparation grade) carried out in the pres-
ence of 10 μMNADH. During our analysis of various mutants,
a prescreen for their response to AMP was gained from a
second run on this column in the presence of 1 mM AMP,
which provided an early classification of whether mutants
behaved more like CtBP1 (with similar elution volumes in both
NADH and AMP) or CtBP2 (with later elution in the presence
of AMP). These results were consistent with the more precise
MALS results reported.
SEC-MALS studies for oligomerization
The CtBP constructs explored by SEC-MALS include the
full C-terminal region—CtBP1 (residues 28–440) and CtBP2
(residues 31–445), each with a six-histidine tag at the amino
terminus. Protein samples were prepared for SEC-MALS by
diluting CtBP stocks to approximately 1.0 mg/ml in SEC-
MALS running buffer (50 mM HEPES, pH 7.4, 300 mM
NaCl, 1 mM EDTA, 2 mM DTT). The protein samples were
filtered with a Costar 0.22 μm Spin-X column at room tem-
perature. After full equilibration of the system with the
SEC-MALS running buffer supplemented by various concen-
trations of NAD(H) moieties, 100 μl protein samples was
injected into the instrument. The SEC-MALS system consisted
of a Dawn Helios-II MALS detector (Wyatt), an Optilab T-rEX
differential refractive index detector (Wyatt), and the 1260
Infinity HPLC system (Agilent) with a TSKgel G3000SWxl
column (Tosoh Bioscience). The experiments performed were
obtained from four different columns, as CtBP use tended to
degrade the columns after 50–100 runs. Cleaning the columns
with 5 M urea improved the column function, however, with a
loss of some resolution in protein separation and variation in
the concentration of protein elution. As a result of column
variability, the data reported in each figure were derived using
the same column and protein stock and were collected within
2 days of each other for direct comparison.
The data for dependence of the molecular mass as a func-
tion of AMP and ADP concentration (Fig. 2) were fit with
Prism 8 (GraphPad Software, Inc) to the equation Y ¼ Lþ
ðU − LÞ =ð1 þ 10logðEC50−xÞnÞ, where L and U are the lower and
upper Mw plateaus, respectively, x is the concentration of
AMP/ADP in μM, and n is the Hill coefficient.
The molecular mass obtained from light scattering from a
heterogeneousmixture of proteinmolecules is the weight average
molecular weight (Mw): Mw = ΣNiM
2
i/ΣNiMi, where Ni is the
molar or fractional concentration (43). Assume that a mixture of
just CtBP dimers and tetramers allows simplification to Mw =
[FT(2MD)
2 + (1 − FT)iMD
2]/[FT(2MD) + (1 − FT)MD], whereMD is
the dimericmolecular weight and FT is the fraction of CtBP in the
tetrameric form. Rearranging this equation, we obtained esti-
mates of the fraction tetramer fromFT= (Mw−MD)/(3MD−Mw).
Crystallization and X-Ray diffraction
Our initial crystallographic experiments to obtain an AMP-
bound CtBP1 (28–375) structure demonstrated clear electron
density indicating bound NAD(H), albeit at less than full oc-
cupancy. Evidently, NAD(H) acquired during bacterial expres-
sion remained bound to CtBP1 during purification. Eventually
we were able to completely remove NAD(H) (definitively
shown by final electron density maps, Fig. 5B) by carrying out
purification in the presence of 5 mM AMP. The final, crucial,
step was a size-exclusion run on an FPLC (ÄTKAprime plus by
GE Healthcare) using a size exclusion column (Highload 16/60
Superdex 200 prep grade) equilibrated with buffer comprising
50 mM Tris:HCl, pH 7.7, 300 mM NaCl, 5 mM EDTA, 2 mM
DTT, and 5 mM AMP. Similar procedures were carried out for
the purification of AMP-bound CtBP1 V185T (28–375) and
CtBP1 L182F/L217V (28–375).
Following purification, the protein was maintained in 5 mM
AMP throughout, concentrated to 8–12 mg/ml and supple-
mented with 2 mM tris(2-carboxyethyl) phosphine (TCEP).
The sample was then filtered with a Costar 0.22 μm Spin-X
column at room temperature. Hanging vapor diffusion drops
were set up in a 1:1 ratio of protein to mother liquor with a
total volume of 4–8 μl and incubated at 20 C. Crystals formed
within 24 h but were allowed to grow for several days. Suitable
crystals with hexagonal bipyramidal morphology grew from
reservoir conditions of 100 mM HEPES buffer pH 7.5 con-
taining 80–200 mM CaCl2 and 2–6% PEG400. A cryogenic
solution was prepared containing 100 mM HEPES buffer, pH
7.5, 200 mM CaCl2, 12% PEG400, and 12% ethylene glycol.
Crystals were equilibrated with this solution by vapor diffusion
for several hours before harvesting by adding the cryo solution
directly to the crystals, mounting, and flash-freezing at 100K.
Diffraction data from wild-type and V185T mutant crystals
were collected on a home source MicroMax-007-HF/Saturn
944 CCD X-ray diffraction system (Rigaku) and then processed
with HKL-3000R (47). Diffraction data from the L182F/V185T
double mutant were kindly collected by Dr Mark Del Campo
on a HyPix-6000HE HPC detector at Rigaku Oxford Diffrac-
tion. The structures were determined by molecular replace-
ment, using the CtBP1 (28–378) crystal structure, PDB ID
code 6CDF (41) as the search molecule, and refined in PHE-
NIX (48). Model building between rounds of refinement was
performed using COOT (49). Refinement was carried out to a
resolution of 2.45 Å for wild-type, 2.35 Å for the V185T
mutant and 2.3 Å for the L182F/V185T mutant (Table 1).
Data availability
The structure factors and coordinates for the crystal struc-
tures described here have been deposited in the Protein Data
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Bank (https://www.rcsb.org) with accession codes 6V89
(CtBP1 [28–375] AMP), 6V8A (CtBP1 [28–375] V185T AMP),
and 7KWM (CtBP1 [28–375] L182F/V185T AMP). All other
data are contained within the document.
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